SPARC.NS - Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited
17-B, Mahal Industrial Estate
Off Mahakali Caves Road Andheri (East)
Mumbai 400093
India
91 22 6645 5645
https://www.sparc.life
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees:
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Anilkumar Raghavan | Chief Exec. Officer | N/A | N/A | 1969 |
| Mr. Chetan M. Rajpara | Chief Financial Officer | 15.14M | N/A | N/A |
| Mr. Siu-Long Yao | Exec. VP Clinical Devel. & Operations | N/A | N/A | N/A |
| Mr. Jaydeep Issrani | Sr. Gen. Mang. of Bus. Devel., Corp. Communication & Investor Relations | N/A | N/A | N/A |
| Mr. Dinesh Poosraj Lahoti | Company Sec. & Compliance Officer | N/A | N/A | N/A |
| Dr. Rajesh Ranganathan | Vice-Pres Corp. Devel. | N/A | N/A | N/A |
| Ms. Shanta Gupta | Chief Human Resource Officer | N/A | N/A | N/A |
| Dr. Nitin K. Damle Ph.D. | Sr. VP & Chief Innovation Officer | N/A | N/A | N/A |
| Mr. Vikram Ramanathan | VP & Head of Translational Devel. | N/A | N/A | N/A |
| Dr. Venkata Palle | Exec. VP & Global Head of Drug Discovery and Preclinical Devel. | N/A | N/A | N/A |
Description
Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet to develop an S1P receptor 1 agonist for autoimmune disorders. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited.
Corporate Governance
Sun Pharma Advanced Research Company Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
